Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2021 - 11 - 11 save search
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
Published: 2021-11-11 (Crawled : 23:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M
|
Health Services
|
| O: 0.18%
H: 1.32%
C: 1.27%
treatment test cancer colorectal cancer her2+ her2- her2
Medicare Publishes Final Local Coverage Determination for Pan-Cancer Immunotherapy Monitoring with Natera's Signatera™ MRD Test
Published: 2021-11-11 (Crawled : 17:00) - prnewswire.com
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: 1.0%
H: 5.18%
C: 4.76%
immunotherapy test therapy cancer
LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
Published: 2021-11-11 (Crawled : 15:15) - globenewswire.com
LVTX | $2.77 -7.05% -7.58% 150K
|
|
| O: 0.02%
H: 2.66%
C: 1.92%
cancer antibody therapy symposium
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
Published: 2021-11-11 (Crawled : 14:00) - biospace.com/
APVO | $0.6827 -7.27% -7.84% 570K
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
cancer antibody immunology preclinical pre-clinical
PNOC Study in Childhood Brain Cancer Enrols First Patient
Published: 2021-11-11 (Crawled : 13:00) - prnewswire.com
KZIA | $0.3951 0.03% 0.03% 100K
|
Health Technology
|
| O: -1.76%
H: 0.59%
C: -1.56%
cancer brain cancer enroll train
NanoString Launches nCounter TCR Diversity Panel and Analysis Package at the 2021 Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2021-11-11 (Crawled : 12:00) - biospace.com/
NSTG M | $0.1053 -37.43% -0.19% 0
|
Health Technology
|
| O: 4.12%
H: 5.61%
C: 5.09%
immunotherapy therapy cancer
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
Published: 2021-11-11 (Crawled : 12:00) - biospace.com/
GLSI | $12.6 -4.11% -4.29% 29K
|
Health Technology
|
| O: 0.11%
H: 0.0%
C: -3.11%
cancer breast cancer conference
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
Published: 2021-11-11 (Crawled : 01:00) - prnewswire.com
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.8%
H: 0.73%
C: 0.64%
phase 2 china cancer phase 2b breast cancer
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.